Joshua M. Lang
A5010695005- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- 3D Printing in Biomedical Research
- PARP inhibition in cancer therapy
- Bladder and Urothelial Cancer Treatments
- Medical Imaging Techniques and Applications
- Metabolism, Diabetes, and Cancer
- Epigenetics and DNA Methylation
- Renal and related cancers
- Molecular Biology Techniques and Applications
- Microfluidic and Bio-sensing Technologies
- Lung Cancer Research Studies
- Fibroblast Growth Factor Research
- Protein Degradation and Inhibitors
University of Wisconsin–Madison
2016-2025
University of Wisconsin Carbone Cancer Center
2016-2025
Wisconsin Division of Public Health
2025
Madison Group (United States)
2013-2024
Wisconsin Institutes for Discovery
2010-2023
UW Health University Hospital
2023
Dana-Farber Cancer Institute
2023
Highland Community College - Illinois
2022
University of California, San Francisco
2014-2021
Duke Cancer Institute
2021
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options localized disease, management of recurrent advanced disease clinicians who treat patients with prostate cancer. portions the guidelines included herein focus on roles germline somatic genetic testing, nomograms tumor multigene molecular androgen deprivation therapy, secondary hormonal chemotherapy, immunotherapy in
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, metastatic disease. Recommendations disease monitoring treatment of recurrent are also included. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. This article summarizes the panel’s discussions 2021 guidelines with regard systemic therapy...
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management localized disease, post-treatment monitoring, treatment recurrence advanced disease. sections included in this article focus metastatic castration-sensitive nonmetastatic castration-resistant cancer (CRPC), CRPC (mCRPC). Androgen deprivation therapy (ADT) intensification is strongly recommended cancer. For CRPC, ADT...
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers microtubule-disrupting agent, monomethyl auristatin E, to cells express Nectin-4. METHODS EV-101 is phase I dose escalation/expansion study enrolled patients with Nectin-4–expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death...
Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in phase I/II multicenter trial (NCT01631552) patients with advanced epithelial cancers. This report summarizes the safety data from overall population (OSP) data, including additional disease cohorts not published previously.Patients refractory metastatic cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, recurrent, metastatic disease. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. These Insights summarizes much of the panel's discussions 4.2022 1.2023 updates guidelines regarding systemic therapy cancer.
The NCCN Guidelines for Prostate Cancer include recommendations staging and risk assessment after a prostate cancer diagnosis the care of patients with localized, regional, recurrent, metastatic disease. These Insights summarize panel's discussions 2024 update to guidelines regard initial stratification, management very-low-risk disease, treatment nonmetastatic recurrence.
BACKGROUND: Androgen deprivation therapy (ADT) with radiotherapy can benefit patients localized prostate cancer. However, ADT negatively impact quality of life, and there remain no validated predictive models to guide its use. METHODS: We used digital pathology images from pretreatment tissue clinical data 5727 enrolled in five phase 3 randomized trials, which treatment was or without ADT, as our source develop validate an artificial intelligence (AI)–derived patient-specific model that...
Tumor cells initiate platelet activation leading to the secretion of bioactive molecules, which promote metastasis. Platelet receptors on tumors have not been well-characterized, resulting in a critical gap knowledge concerning platelet-promoted We identify direct interaction between platelets and tumor CD97 that stimulates rapid bidirectional signaling. CD97, an adhesion G protein-coupled receptor (GPCR), is overexpressed antigen several cancer types. Purified extracellular domain or...
Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way develop strategies for monitoring and inhibiting in castration-resistant (CRPC). The purpose of this study was understand whether other AR variants may be coexpressed with promote Experimental Design: We utilized complementary short- long-read sequencing intact mRNA isoforms characterize...
Previous studies in HIV-infected individuals have demonstrated serum albumin to be strongly associated with kidney function decline, independent of urine and inflammatory markers. Lower concentrations may an under-appreciated risk factor for decline elders. We performed a cohort analysis the Health Aging Body Composition Study, well-functioning, bi-racial, community-dwelling elders between age 70 79 years. examined associations concentration longitudinal by estimated glomerular filtration...
Analysis of DNA methylation is a valuable tool to understand disease progression and increasingly being used create diagnostic prognostic clinical biomarkers. While conversion cytosine 5-methylcytosine (5mC) commonly results in transcriptional repression, further 5-hydroxymethylcytosine (5hmC) associated with activation. Here we perform the first study integrating whole-genome 5hmC DNA, 5mC, transcriptome sequencing samples benign, localized, advanced prostate cancer. shown mark activation...
TPS290 Background: Patients with mCRPC inevitably develop resistance to available therapies and lack curative options. In patients treated novel hormonal agents (NHAs), mutations can in the ligand-binding domain (LBD) of AR gene, some which are associated current disease progression. ARV-766 is a novel, potent, orally bioavailable proteolysis targeting chimera (PROTAC) protein degrader that degrades not only wild-type but also clinically relevant LBD mutants, including most prevalent L702H,...
5011 Background: Patients with mCRPC inevitably develop resistance to available therapies, eg, novel hormonal agents (NHAs), and experience disease progression. Certain mutations that can in the ligand-binding domain (LBD; amino acids 671–920) of AR gene during treatment have been associated poor outcomes. ARV-766 is a novel, potent, orally administered PROTAC degrader targets wild-type clinically relevant LBD mutants, including most prevalent L702H, H875Y, T878A mutations. We report initial...
To test for a role of the calcineurin-NFAT (nuclear factor activated T cells) pathway in regulation fiber type-specific gene expression, slow and fast muscle-specific promoters were examined C2C12 myotubes muscle presence calcineurin or NFAT2 expression plasmids. Overexpression active induced both but not non-muscle-specific reporters. did activate promoters, although it strongly an NFAT reporter. Thus overexpression activates transcription vitro likely via factor. Slow myosin light chain 2...
Purpose: Creative expression (CE) programs are emerging interventions to improve the quality of care and life persons with dementia (PWDs) in long-term settings. However, limited empirical evidence exists support effectiveness these programs. Here, we report findings from an assessment impact TimeSlips (TS), a group storytelling program that encourages CE among PWDs those who for them. Design Methods: Instruction TS was provided through 10-week on-site training. An observational study using...
Abstract Purpose: There is a critical clinical need for new predictive and pharmacodynamic biomarkers that evaluate pathway activity in patients treated with targeted therapies. A microscale platform known as VERSA (versatile exclusion-based rare sample analysis) was developed to integrate readouts across protein, mRNA, DNA circulating tumor cells (CTC) comprehensive analysis of the androgen receptor (AR) signaling pathway. Experimental Design: Utilizing preparation principles, handheld chip...